Worsening Neobladder Incontinence in a Patient on Nivolumab Therapy

Urology. 2024 May:187:92-93. doi: 10.1016/j.urology.2024.02.036. Epub 2024 Feb 28.

Authors

Melissa Moran¹, Juliana E Kim¹, Melinda Z Fu¹, Saum Ghodoussipour²

Affiliations

¹ Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
² Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ; Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Division of Urology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ. Electronic address: [email protected].

PMID: 38423394
DOI: 10.1016/j.urology.2024.02.036

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents, Immunological / adverse effects
Humans
Male
Middle Aged
Nivolumab* / adverse effects
Urinary Bladder Neoplasms / drug therapy
Urinary Bladder Neoplasms / surgery
Urinary Incontinence* / chemically induced
Urinary Incontinence* / etiology
Urinary Reservoirs, Continent / adverse effects

Substances

Nivolumab
Antineoplastic Agents, Immunological